

Bibliography

- ◆ Anderson F, Audet AM. Preventing Deep Vein Thrombosis and Pulmonary Embolism: A Practical Guide to Evaluation and Improvement. Center for Outcomes Research, UMass Medical School. 1998. Available at: http://www.outcomes-umassmed.org/DVT/best_practice/ Last accessed November 2011
- ◆ Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126,(3 Suppl)204S-233S
- ◆ Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J*.2007 Jul;28(13):1598-660
- ◆ Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N.Engl.J.Med*. 2010;363,(26)2499-2510
- ◆ Benjamin E, Wolf P, D'Agostino R, et al. Impact of Atrial Fibrillation on the Risk of Death. *Circulation*. 1998;98:946-952
- ◆ Bramlage P, Pittrow D, & Kirch W Current concepts for the prevention of venous thromboembolism. *Eur.J.Clin.Invest*. 2005;35 Suppl 1,4-11
- ◆ Briffa T, Hickling S, Knuiman M, et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. *BMJ*. 2009;338,b36
- ◆ CDC. Atrial Fibrillation Fact Sheet. Available at: http://www.cdc.gov/dhdsdp/data_statistics/fact_sheets/docs/fs_atrial_fibrillation.pdf Last accessed November 2011
- ◆ Clinicaltrials.gov. An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome. Available at <http://clinicaltrials.gov/ct2/show/NCT00809965?term=rivaroxaban&rank=4> Last accessed November 2011
- ◆ Clinicaltrials.gov. Available at <http://clinicaltrials.gov/ct2/show/NCT00439777?term=EINSTEIN+PE&rank=1>. Last accessed November 2011
- ◆ Clinicaltrials.gov. Available at http://clinicaltrials.gov/ct2/results?term=rivaroxaban&show_flds=Y. Last accessed November 2011
- ◆ Coalition to Prevent VTE. Venous thromboembolism: prevention and treatment background. Available at: http://www.coalitiontopreventvte.org/index.cfm/t/VTE_prevention_and_treatment/vid/49D3BA86-1422-16B3-78B8FAB696D75667 Last accessed November 2011
- ◆ Coalition to Prevent VTE. The Burden of VTE. Available at: http://www.coalitiontopreventvte.org/index.cfm/t/The_burden_of_VTE/vid/DCD0A03F-1422-16B3-78E0B9EB057196F2 Last accessed November 2011
- ◆ Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb.Haemost*. 2007;98,(4)756-764
- ◆ Cohen AT, Büller H, Mebazaa A et al. Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients (MAGELLAN). Available at http://my.americanheart.org/professional/Sessions/AdditionalMeetings/AdditionalMeetingsResources/ACC-2011-MAGELLAN_UCM_425291_Article.jsp. Last accessed November 2011





- ◆ Dantas GC, Thompson BV, Manson JA, et al. Patients' perspectives on taking warfarin: qualitative study in family practice. *BMC.Fam.Pract.* 2004;5,15
- ◆ Data on file. Bayer Pharma AG, Berlin, Germany
- ◆ eMC. Arixtra® SPC. Available at: <http://www.medicines.org.uk/emc/medicine/15123/SPC/> Last accessed November 2011
- ◆ eMC. Clexane® SPC. Available at: <http://www.medicines.org.uk/EMC/medicine/24345/SPC/Clexane+pre-filled+syringes/> Last accessed November 2011
- ◆ eMC. Warfarin SPC. Available at: <http://www.medicines.org.uk/EMC/medicine/21578/SPC/Warfarin+3+mg+Tablets/> Last accessed November 2011
- ◆ Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N.Engl.J.Med.* 2008;358,(26)2765-2775
- ◆ Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. *J Bone Joint Surg [Br]*. 2009;91-B:636-44
- ◆ Ezekowitz MD & Falk RH The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. *Mayo Clin.Proc.* 2004;79,(7)904-913
- ◆ Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA.* 2001;285,(22)2864-2870
- ◆ Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133,(6 Suppl)381S-453S
- ◆ Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126, (3 Suppl) 338S-400S
- ◆ Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. *Stroke.* 2009;40(1):235-240
- ◆ Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA.* 2001;285,(18)2370-2375
- ◆ Goldhaber SZ & Morrison RB Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. *Circulation.* 2002;106,(12)1436-1438
- ◆ Gomez-Outes A, Suarez-Gea ML, Blazquez-Perez A, et al. Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient? *J Thromb Haemost.* 2009; 7: 2149-51
- ◆ Grech ED & Ramsdale DR Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. *BMJ.* 2003;326,(7401)1259-1261
- ◆ Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. *J Thromb Thrombolysis.* 2008;25(1):52-60
- ◆ Haas S & Lassen MR Venous thromboembolism after elective hip and knee replacement surgery. *European Journal of Hospital Pharmacy Practice.* 2011;16
- ◆ Hart RG, Pearce LA, & Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann.Intern.Med.* 2007;146,(12)857-867
- ◆ Heit JA The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J.Thromb.Thrombolysis.* 2006;21,(1)23-29
- ◆ Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. *Circulation.* 2001;103,(24)2994-3018



RIVAROXABAN



- ◆ Hori M, Matsumoto M, Tanahashi N, et al. The safety and efficacy of Rivaroxaban for prevention of stroke in Japanese patients with non-valvular atrial fibrillation (J-Rocket AF) (2011) Monday, 25 July 2011. *JTH* 2011;9 (suppl. 2) 20. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2011.04380_1.x/citedby. Last accessed November 2011
- ◆ Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. *Int.J.Cardiol.* 2009;137,(2)102-107
- ◆ Internet stroke centre. About stroke. Available at <http://www.strokecenter.org/patients/stats.htm> Last accessed November 2011
- ◆ Jang IK & Hursting MJ When heparins promote thrombosis: review of heparin-induced thrombocytopenia. *Circulation.* 2005;111,(20)2671-2683
- ◆ Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet.* 2008;372,(9632)31-39
- ◆ Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. *Med Clin North Am.* 2008;92:17-40
- ◆ Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol.* 1998;82(8A):2N-9N
- ◆ Kearon C Natural history of venous thromboembolism. *Circulation.* 2003;107,(23 Suppl 1)I22-I30
- ◆ Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N.Engl.J.Med.* 2008;358,(26)2776-2786
- ◆ Lin HJ, Wolf P, Kelly-Hayes M, et al. Stroke Severity in Atrial Fibrillation: The Framingham Study. *Stroke.* 1996; 27:1760-1764
- ◆ Lip GY & Lim HS Atrial fibrillation and stroke prevention. *Lancet Neurol.* 2007;6,(11)981-993
- ◆ Liu S, Shi HB, Gu JP, et al. Massive pulmonary embolism: treatment with the rotarex thrombectomy system. *Cardiovasc.Intervent.Radiol.* 2011;34,(1)106-113
- ◆ Mackay J, Mensah, G. Deaths from coronary heart disease. The Atlas of Heart Disease and Stroke. United Kingdom. World Health Organization 2004. Available at http://www.who.int/cardiovascular_diseases/resources/atlas/en/ Last accessed November 2011
- ◆ Mackay J, Mensah, G. Global burden of stroke. The Atlas of Heart Disease and Stroke. United Kingdom. World Health Organization 2004. Available at http://www.who.int/cardiovascular_diseases/resources/atlas/en/ Last accessed November 2011
- ◆ Mann KG, Brummel K, & Butenas S What is all that thrombin for? *J.Thromb.Haemost.* 2003;1,(7)1504-1514
- ◆ Marini C, De SF, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. *Stroke.* 2005a;36,(6)1115-1119
- ◆ Medscape. Anticoagulation Therapy for Venous Thromboembolism. *Medscape General Medicine.* 2004;6,(3)5
- ◆ Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet.* 2009;374,(9683)29-38
- ◆ Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. *N.Engl.J.Med.* 2011; [Epub ahead of print]




RIVAROXABAN



- ◆ Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114,(2)119-125
- ◆ Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost*. 2007;5(4):692-699
- ◆ News Medical. What is a stroke? Available at <http://www.news-medical.net/health/What-is-a-Stroke.aspx> Last accessed November 2011
- ◆ NHS choices. Atrial fibrillation. Available at <http://www.nhs.uk/Conditions/Atrial-fibrillation> Last accessed November 2011
- ◆ NHS choices. Atrial fibrillation. Available at <http://www.nhs.uk/Conditions/Atrialfibrillation/Pages/Complications.aspx>. Last accessed November 2011
- ◆ Nijkeuter M, Söhne M, Tick L et al. The Natural Course of Hemodynamically Stable Pulmonary Embolism. Clinical Outcome and Risk Factors in a Large Prospective Cohort Study. *Chest*. 2007; 131(2) 517-523
- ◆ Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883-891
- ◆ Patient UK. Deep vein thrombosis. Available at: <http://www.patient.co.uk/health/Deep-Vein-Thrombosis.htm> Last accessed November 2011
- ◆ Pesaro AE, Corrêa TD, Forlenza L, et al. Acute coronary syndromes: how to make a correct diagnosis in the emergency room. *Einstein*. 2007;5,(1)80-84
- ◆ Riley RS. What you should know about abnormal blood clotting. Available online at: <http://www.pathology.vcu.edu/news/minimed/Trombophilia.pdf> Last accessed November 2011
- ◆ Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. *Circulation*. 2011;123(4):e18-e209
- ◆ Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol*. 2006;47,(10)2130-2139
- ◆ Turpie AG. Burden of disease: medical and economic impact of acute coronary syndromes. *Am J Manag Care*. 2006;12,(16 Suppl)S430-S434
- ◆ Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. *Arterioscler Thromb Vasc Biol*. 2007;27,(6)1238-1247
- ◆ Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009;373,(9676)1673-1680
- ◆ Turpie AG. Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. *European Instructional Lectures*. 2009;9,29-38
- ◆ United Nations. World Population Ageing. Available at: <http://www.un.org/esa/population/publications/WPA2009/WPA2009-report.pdf>. Last accessed November 2011
- ◆ World Health Report 2000 - Health Systems: Improving Performance. Geneva. World Health Organization 2000. Available at <http://www.who.int/whr/en/> Last accessed November 2011
- ◆ Woodward T, Kachroo S, Bookhar BK, et al. Systematic review of the economic burden of venous thromboembolism treatment. Paper presented at ISPOR 15th Annual International Meeting; May 2010; Atlanta, GA. Abstract PCV60



RIVAROXABAN



- ◆ World Health Statistics 2008. Geneva. World Health Organization, 2008. Available at http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf Last accessed November 2011
- ◆ Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N.Engl.J.Med.* 2001;345,(7)494-502
- ◆ [No author listed] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002

About Rivaroxaban (Xarelto®)

Rivaroxaban is an oral anticoagulant that was discovered in Bayer HealthCare's Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. It has a rapid onset of action with a predictable dose response and high bioavailability, no requirement for routine coagulation monitoring, and a limited potential for food and drug interactions.

Rivaroxaban is marketed under the brand name Xarelto® for VTE prevention in adult patients following elective hip or knee replacement surgery, and it is the only oral anticoagulant that has consistently demonstrated superior efficacy over enoxaparin in this indication. Rivaroxaban is approved in more than 110 countries worldwide and marketed outside the U.S. by Bayer HealthCare in this indication.

In the U.S., where rivaroxaban has been available since July 2011 for VTE prevention in adult patients following elective hip or knee replacement surgery, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company) holds marketing rights. The Bayer HealthCare sales force is supporting Janssen Pharmaceuticals, Inc. in designated hospital accounts. On November 4, Xarelto® received further marketing approval in the U.S. for the prevention of stroke in patients with Atrial Fibrillation.

The extensive clinical trial programme supporting rivaroxaban makes it the most studied and widely published oral, direct Factor Xa inhibitor. The studies, reported and ongoing, involve over 75,000 patients for the prevention and treatment of venous and arterial thromboembolic (VAT) disorders across a broad range of acute and chronic conditions, including stroke prevention in patients with Atrial Fibrillation, DVT treatment and the prevention of recurrent DVT or PE, and the secondary prevention of Acute Coronary Syndrome.

**To learn more about thrombosis, please visit www.thrombosisadviser.com
To learn more about 'Xarelto' please visit www.xarelto.com**



RIVAROXABAN